Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig

Corresponding author: Shi Hu

Affiliations: Second Military Medical University

Publication date: this article was published online on April 24, 2020



The researchers generate a recombinant protein by connecting the extracellular domain of human ACE2 to the Fc region of the human immunoglobulin IgG1. A fusion protein containing an ACE2 mutant with low catalytic activity is also used in this study. The fusion proteins are then characterized. Both fusion proteins have a high binding affinity for the receptor-binding domains of SARS-CoV and SARS-CoV-2 and exhibit desirable pharmacological properties in mice. Moreover, they also demonstrated that the fusion proteins neutralize virus pseudotyped with SARS-CoV or SARS-CoV-2 spike proteins in vitro.

Nomination Reason

This work reveal that an ACE2-Ig exhibit cross-reactivity against coronaviruses, and have potential applications in the diagnosis, prophylaxis, and treatment of SARS-CoV-2.


This article has been nominated for Distinguished Research Awards, you can visit the website below and vote for the nominated publications:

3 Reply

Have the author test it in vivo?

This work highlight the usage of ACE2 protein in COVID19, it is very useful!

About Us · User Accounts and Benefits · Privacy Policy · Management Center · FAQs
© 2020 MolecularCloud